Exploring the Role of CDK4/6 Inhibitors in HR+ HER2- Breast Cancer: From the Adjuvant to the Metastatic Setting

Novartis Pharma Schweiz AG

Wednesday, 19.11.2025, 12:30 - 13:30, Boston 1-2

Advancing the Standard: Anti-BCMA Modalities in the Management of Early Multiple Myeloma Relapse

GSK

Wednesday, 19.11.2025, 12:30 - 13:30, Shanghai 3-4

Advancing treatment for ES-SCLC: innovations in precision medicine

Amgen

Wednesday, 19.11.2025, 12:30 - 13:30, Delhi

Expert Panel on CLL: Personalized Therapy Strategies for Clinical Practice

Abbvie

Thursday, 20.11.2025, 12:30 - 13:30, Boston 1-2

Unlocking the Potential of ADCs: Novel Approaches in Ovarian Cancers

Abbvie

Thursday, 20.11.2025, 12:30 - 13:30, Shanghai 1-2

Treatment Strategies in Multiple Myeloma: Insights from Clinical Practice

Pfizer

Thursday, 20.11.2025, 12:30 - 13:30, Shanghai 3-4

Focus on QoL and tolerability in CML-CP: Status, limitations and latest advances

Novartis Pharma Schweiz AG

Thursday, 20.11.2025, 12:30 - 13:30, Kairo 1-2

Redefining Treatment Paradigms for CLL Patients Pretreated with Covalent BTK Inhibitors

Eli Lilly and Company

Friday, 21.11.2025, 12:30 - 13:30, Boston 1-2

Advancing Outcomes with Data-Driven Insights in Solid Tumors (Breast & Lung Cancer)

Pfizer

Friday, 21.11.2025, 12:30 - 13:30, Shanghai 1-2

From bench to bedside: Clinical use of the CRISPR/Cas technology

Vertex Pharmaceuticals GmbH

Friday, 21.11.2025, 12:30 - 13:30, Shanghai 3-4